NCT03444376View on ClinicalTrials.gov

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

April 29, 2022

Study Completion Date

December 21, 2023

Conditions
Cervical Cancer
Interventions
DRUG

GX-188E

GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device

DRUG

KEYTRUDA®

pembrolizumab(100mg/4mL/vial), Intravenous administration

Trial Locations (9)

10408

National Cancer Center, Gyeonggi-do

13620

Seoul National University Bundang Hospital, Gyeonggi-do

42601

Keimyung University Dongsan Medical Center, Daegu

Unknown

Inje University Busan Paik Hospital, Busan

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

152-703

Korea University Guro Hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Genexine, Inc.

INDUSTRY

NCT03444376 - The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer | Biotech Hunter | Biotech Hunter